CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023		Dec. 31, 2022	Dec. 31, 2021
Revenue:
Revenue	$ 638,764		$ 801,536	$ 670,534
Costs and operating expenses:
Cost of product revenue	353,922		345,830	279,280
Research and development	42,722		43,936	34,274
Selling, general and administrative	218,113		215,829	183,866
Contingent consideration	(30,569)		(28,729)	5,865
Total costs and operating expenses	584,188		576,866	503,285
Income from operations	54,576		224,670	167,249
Other income (expenses):
Investment income	24,135		6,978	176
Interest expense	(1,951)		(1,162)	(11,278)
Loss on extinguishment of debt	(12,676)		0	0
Amortization of debt issuance costs	(8,075)		(1,815)	(1,436)
Other income (expenses)	8,123		(9,531)	(1,168)
Other income (expenses), net	9,556		(5,530)	(13,706)
Income before income taxes	64,132		219,140	153,543
Income tax provision	22,555		33,181	25,252
Net income	$ 41,577		$ 185,959	$ 128,291
Earnings per share:
Basic	$ 0.75		$ 3.35	$ 2.33
Diluted	$ 0.74		$ 3.24	$ 2.24
Weighted average common shares outstanding:
Basic	55,720		55,460	55,015
Diluted	56,377		57,455	57,264
Net Income (Loss)	$ 41,577		$ 185,959	$ 128,291
Other comprehensive income (loss):
Foreign currency translation adjustment	(3,037)		(17,508)	(18,971)
Comprehensive income	38,540		168,451	109,320
Products
Revenue:
Revenue	638,381	[1]	801,183	670,319
Royalty and Other Revenue
Revenue:
Revenue	$ 383		$ 353	$ 215

[1] 2023 revenue for filtration products includes revenue related to FlexBiosys, Inc. (“FlexBiosys”) from April 17, 2023, as well as Metenova Holding AB (“Metenova”) from October 2, 2023.